George Ansstas

3.3k total citations
75 papers, 1.1k citations indexed

About

George Ansstas is a scholar working on Oncology, Genetics and Immunology. According to data from OpenAlex, George Ansstas has authored 75 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 32 papers in Genetics and 17 papers in Immunology. Recurrent topics in George Ansstas's work include Glioma Diagnosis and Treatment (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and CAR-T cell therapy research (15 papers). George Ansstas is often cited by papers focused on Glioma Diagnosis and Treatment (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and CAR-T cell therapy research (15 papers). George Ansstas collaborates with scholars based in United States, Australia and Canada. George Ansstas's co-authors include Tanner M. Johanns, John F. DiPersio, Michael P. Rettig, Karam Khaddour, Sonika Dahiya, Jiayi Huang, Cole Ferguson, Christina Tsien, Gavin P. Dunn and Jian Campian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

George Ansstas

67 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George Ansstas United States	17	471	428	337	277	181	75	1.1k
Andrea M. Griesinger United States	17	300 0.6×	439 1.0×	759 2.3×	224 0.8×	196 1.1×	37	1.3k
Vinay Sagar United States	19	361 0.8×	190 0.4×	712 2.1×	142 0.5×	231 1.3×	46	1.3k
Andrew J. Tsung United States	25	352 0.7×	366 0.9×	706 2.1×	284 1.0×	495 2.7×	54	1.5k
Zev A. Binder United States	22	475 1.0×	426 1.0×	476 1.4×	237 0.9×	283 1.6×	69	1.2k
Rolf Warta Germany	21	335 0.7×	347 0.8×	532 1.6×	261 0.9×	324 1.8×	53	1.2k
Sergey Popov United Kingdom	20	316 0.7×	358 0.8×	825 2.4×	177 0.6×	349 1.9×	48	1.5k
Marianna B. Ruzinova United States	15	504 1.1×	138 0.3×	822 2.4×	225 0.8×	286 1.6×	36	1.4k
Caroline Delmas France	22	408 0.9×	343 0.8×	794 2.4×	139 0.5×	433 2.4×	37	1.4k
Elena I. Fomchenko United States	13	605 1.3×	582 1.4×	773 2.3×	152 0.5×	388 2.1×	23	1.5k
Catherine Richon France	18	391 0.8×	233 0.5×	608 1.8×	243 0.9×	419 2.3×	32	1.2k

Countries citing papers authored by George Ansstas

Since Specialization

Citations

This map shows the geographic impact of George Ansstas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Ansstas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Ansstas more than expected).

Fields of papers citing papers by George Ansstas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Ansstas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Ansstas. The network helps show where George Ansstas may publish in the future.

Co-authorship network of co-authors of George Ansstas

This figure shows the co-authorship network connecting the top 25 collaborators of George Ansstas. A scholar is included among the top collaborators of George Ansstas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Ansstas. George Ansstas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Keenan, Bridget P., Mahesh Yadav, George Ansstas, et al.. (2025). Intratumoral heterogeneity and immunotherapy resistance: clinical implications. Annals of Oncology. 37(3). 314–328. 1 indexed citations

Sullivan, Ryan J., J.C. Hassel, Teresa Amaral, et al.. (2025). 954P A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001). Annals of Oncology. 36. S585–S585.

Adeyelu, Tolulope, Andrew Elliott, Farah Abdulla, et al.. (2024). Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma. npj Precision Oncology. 8(1). 187–187. 7 indexed citations

Huang, Jiayi, Jian Campian, T.A. DeWees, et al.. (2024). A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 120(3). 738–749. 11 indexed citations

Adeyelu, Tolulope, Andrew Elliott, Farah Abdulla, et al.. (2024). ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes. Scientific Reports. 14(1). 3444–3444. 6 indexed citations

Ansstas, George, et al.. (2023). 553 Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma. SHILAP Revista de lepidopterología. A631–A631.

Khattak, Adnan, Jeffrey S. Weber, Tarek Meniawy, et al.. (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.. Journal of Clinical Oncology. 41(17_suppl). LBA9503–LBA9503. 50 indexed citations

Chen, David Y., et al.. (2023). Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. Frontiers in Medicine. 10. 1090737–1090737. 10 indexed citations

Zhou, Alice Y., et al.. (2023). Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity. Journal of the National Comprehensive Cancer Network. 21(7). 688–693.e3. 8 indexed citations

10.

Weber, Jeffrey S., Adnan Khattak, Matteo S. Carlino, et al.. (2023). LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. Annals of Oncology. 34. S1288–S1289. 5 indexed citations

11.

Luo, Jingqin, Emily A. Slat, Katherine N. Weilbaecher, et al.. (2022). A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Neuro-Oncology Practice. 9(3). 193–200. 21 indexed citations

12.

Hwang, Helen, Jiayi Huang, Karam Khaddour, et al.. (2022). Prolonged response of recurrent IDH -wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab. CNS Oncology. 11(1). 23 indexed citations

13.

Kasi, Pashtoon Murtaza, Sakti Chakrabarti, Sarah Sawyer, et al.. (2022). BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. BMJ Open. 12(5). e060342–e060342. 9 indexed citations

14.

Butt, Omar H., Alice Y. Zhou, Jiayi Huang, et al.. (2021). A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab164–vdab164. 38 indexed citations

15.

Ma, Si‐Rui, Soumon Rudra, Jian Campian, et al.. (2021). Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma. Neuro-Oncology Advances. 3(1). vdab081–vdab081. 1 indexed citations

16.

Ansstas, George, et al.. (2021). Racial and socioeconomic differences in acral lentiginous melanoma outcomes: A Surveillance, Epidemiology, and End Results analysis. Journal of the American Academy of Dermatology. 87(4). 866–867. 5 indexed citations

17.

Leaf, Rebecca Karp, Deepa Rangachari, James W. Mier, et al.. (2019). Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology. 94(5). 563–574. 49 indexed citations

18.

Huang, Jiayi, Jian Campian, Amit D. Gujar, et al.. (2018). Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. Journal of Neuro-Oncology. 138(1). 105–111. 45 indexed citations

19.

Johanns, Tanner M., Christopher A. Miller, Ian G. Dorward, et al.. (2016). Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discovery. 6(11). 1230–1236. 209 indexed citations

20.

Huang, Jiayi, Pamela Samson, Stephanie M. Perkins, et al.. (2016). Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. Journal of Neuro-Oncology. 131(3). 593–601. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact